BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.380
-0.010 (-0.42%)
Nov 4, 2024, 4:00 PM EST - Market closed
BioCardia Revenue
BioCardia had revenue of $3.00K in the quarter ending June 30, 2024, a decrease of -93.02%. This brings the company's revenue in the last twelve months to $428.00K, up 0.71% year-over-year. In the year 2023, BioCardia had annual revenue of $477.00K, down -64.72%.
Revenue (ttm)
$428.00K
Revenue Growth
+0.71%
P/S Ratio
9.03
Revenue / Employee
$21,400
Employees
20
Market Cap
8.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
XWELL | 32.88M |
Streamline Health Solutions | 20.30M |
Ensysce Biosciences | 1.44M |
Soligenix | 494.62K |
Vaccinex | 356.00K |
Virax Biolabs Group | 156.42K |
Cardio Diagnostics Holdings | 39.14K |
BCDA News
- 6 weeks ago - BioCardia Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family - GlobeNewsWire
- 2 months ago - FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application - GlobeNewsWire
- 5 months ago - BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach - GlobeNewsWire